Advertisement

Topics

Summit Therapeutics awarded BARDA contract to develop Ridinilazole for CDI

03:37 EDT 13 Sep 2017 | Pharmaceutical Business Review

Summit Therapeutics announces that the Biomedical Advanced Research and Development Authority (BARDA), an agency of the US government's Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response, has awarded Summit a contract worth up to $62m.

Original Article: Summit Therapeutics awarded BARDA contract to develop Ridinilazole for CDI

NEXT ARTICLE

More From BioPortfolio on "Summit Therapeutics awarded BARDA contract to develop Ridinilazole for CDI"

Quick Search
Advertisement